Do SGLT2 inhibitors protect elderly patients from HF rehospitalization and CKD progression? More opportunities than concerns

The pace of population aging in developed countries is much faster than in the past. Meanwhile, in order to treat highly prevalent diseases such as diabetes, heart failure (HF) and chronic kidney disease (CKD), new options are emerging. Sodium glucose co-transporter inhibitors (SGLT2i) were shown to drastically reduce the risk of mortality, rehospitalization for HF and decline of renal function in diabetic and non-diabetic patients [1]. However, randomized controlled trials (RCTs), designed for ascertaining the efficacy and the safety of such treatment, were not tailored to elderly cohorts.